山东新华制药股份有限公司 关于取得二十碳五烯酸乙酯软胶囊药品注册证书的公告 证券代码：000756 证券简称：新华制药 公告编号：2025-35 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 近日，山东新华制药股份有限公司（"新华制药"或"本公司"）收到国家药品监督管理 局核准签发的二十碳五烯酸乙酯软胶囊（以下简称"本品"）《药品注册证书》，现将相关情 况公告如下： 一、基本情况 药品名称：二十碳五烯酸乙酯软胶囊 剂型：胶囊剂 规格：1.0g；0.5g 药品分类：处方药 注册分类：化学药品4类 申请人：山东新华制药股份有限公司 申请事项：药品注册（境内生产） 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附 执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 二、 其他相关信息 2023年11月，新华制药向国家药品监督管理局药品审评中心（CDE）递交二十碳五烯酸 乙酯软胶囊上市许可注册申报资料并获受理，2025年6月获得《药品注册证书》 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [4]. Core Insights - The upcoming 2025 ASCO conference highlights the impressive presence of Chinese innovative pharmaceutical companies, with over 70 research projects selected, indicating a robust growth in domestic drug development [2][22]. - The report emphasizes the structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments [3]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 1.78%, outperforming the CSI 300 index by 1.96 percentage points and the ChiNext index by 2.83 percentage points, ranking first among 31 sub-industries [1][16]. - The Hong Kong Hang Seng Medical Health Index increased by 5.54%, surpassing the Hang Seng National Enterprises Index by 4.18 percentage points [1][16]. Company Research Progress - Recent developments include the IND application for HS-10510 by Haosen Pharmaceutical and ongoing clinical trials for several drugs from companies like Hengrui Medicine and BeiGene [35]. Key Company Highlights - Hengrui Medicine has 69 research projects selected for the ASCO conference, covering various cancer types, showcasing its leadership in innovative drug development [23][26]. - Innovent Biologics will present clinical data for IBI363 and IBI343 at ASCO, indicating its strong pipeline in cancer immunotherapy [27][28]. - Rongchang Biopharmaceutical has over 20 clinical progress reports accepted for presentation at ASCO, focusing on ADC therapies for various cancers [30][31]. Investment Recommendations - The report recommends focusing on companies such as Hengrui Medicine, Mindray Medical, United Imaging Healthcare, and Yuyue Medical, based on their strong market positions and growth potential [3].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [4]. Core Insights - The upcoming 2025 ASCO conference highlights the impressive presence of Chinese innovative pharmaceutical companies, with over 70 research projects selected, indicating a robust growth in domestic drug development [2][22]. - The report emphasizes the increasing competitiveness of domestic drugs in the global market, particularly in oncology, as several innovative drugs are making significant progress [2][23]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 1.78%, outperforming the CSI 300 index by 1.96 percentage points and the ChiNext index by 2.83 percentage points, ranking first among 31 sub-industries [1][16]. - The Hong Kong Hang Seng Healthcare Index increased by 5.54%, surpassing the Hang Seng Index by 4.18 percentage points [1][16]. Company Research Progress - Recent developments include the IND application for HS-10510 by Haosen Pharmaceutical and ongoing clinical trials for several drugs by companies such as Hengrui Medicine and BeiGene [35]. Key Company Highlights - Hengrui Medicine has 69 research projects selected for the ASCO conference, covering various cancer types, showcasing its leadership in innovative drug development [23][26]. - Innovent Biologics will present clinical data for IBI363 and IBI343 at ASCO, indicating its strong pipeline in oncology [27][28]. - Rongchang Biopharmaceutical has over 20 clinical progress reports accepted for presentation at ASCO, focusing on various cancer treatments [30][31]. Investment Strategy - The report suggests a structural selection of investment opportunities based on payment willingness and ability, focusing on three main areas: hospital payment support, expansion of consumer demand, and overseas market opportunities [3]. Key recommendations include Hengrui Medicine, Mindray Medical, United Imaging Healthcare, and Yuyue Medical [3].

Group 1 - The China Securities Regulatory Commission (CSRC) is promoting the implementation of the fifth listing standard for the Sci-Tech Innovation Board, which supports high-quality red-chip technology companies to return to domestic listings [2] - The fifth listing standard will allow unprofitable companies with high technological content and excellent overall quality to apply for listing, indicating a potential influx of companies seeking to utilize this standard [2] - Supportive policies are emerging, including backing for red-chip technology companies to return to the domestic market and encouraging private equity funds to acquire listed companies for industrial integration [2] Group 2 - Securities firms are experiencing a new round of interest rate cuts, with customer margin interest rates dropping to 0.05%, following banks' reductions in deposit rates [3] - The reduction in margin interest rates has been a trend over the past couple of years, decreasing from 0.25% to 0.05%, which may impact the interest income of securities firms [3] - Investors with idle funds in margin accounts are encouraged to seek higher returns through margin financial products available on brokerage apps [3] Group 3 - The recent deposit rate cuts are expected to positively impact banks' interest margins, allowing them to increase government bond allocations to support the real economy [4] - The valuation recovery logic driven by bank stock dividends is anticipated to continue, with limited downward pressure on net interest margins and stable earnings [4] - Institutional reforms, such as new public fund regulations and the influx of medium to long-term capital, are expected to enhance the attractiveness of the banking sector [4] Group 4 - The reduction in deposit rates by 18 national banks has led to a situation where fixed-term deposits are yielding less than wealth management products, prompting a potential shift of funds towards higher-yield assets [5][6] - The decline in deposit rates is seen as beneficial for banks in controlling interest costs, but it may also increase the difficulty of attracting deposits [6] Group 5 - The significant increase in securities transaction stamp duty, which rose to 53.5 billion yuan in the first four months of the year, reflects a notable uptick in capital market activity [7] - The growth in stamp duty revenue, despite a halving of the tax rate, indicates a more active capital market and signals the government's commitment to maintaining market stability [7] - Upcoming reforms in the Sci-Tech Innovation Board and the continuous application of AI across industries are expected to further invigorate market activity and support the real economy [7] Group 6 - Xiaomi has officially launched its first SUV model, the Xiaomi YU7, positioning it as a luxury high-performance vehicle, with significant investments in chip development and a long-term R&D plan [9] - The company has invested over 13.5 billion yuan in its chip project, with a team of 2,500 people, and plans to exceed 6 billion yuan in R&D spending this year [9] Group 7 - The mid-term strategies of securities firms emphasize technology innovation as a core topic, aligning with national economic goals for 2025 [13] - The focus on technology innovation is expected to drive investment opportunities in sectors such as AI, semiconductors, high-end manufacturing, and green economy [13] - The attractiveness of Chinese assets is increasing, with institutions viewing them as a safe haven and long-term investment option amid global uncertainties [13]

Group 1 - Company Zhongnan Media signed a government procurement contract worth 1.009 billion yuan for the supply of free textbooks and related teaching resources in Hunan Province for 2025, ensuring stable revenue for the company [1] - Company Zhongnan Media was established in December 2008, focusing on the publishing, distribution, and printing of publications [2] Group 2 - Company Tongling Nonferrous Metals announced the resignation of its general manager and deputy general manager due to higher-level assignments [3] - Company Tongling Nonferrous Metals was founded in November 1996, primarily engaged in the mining and processing of copper, iron, and sulfur gold [4] Group 3 - Company Xinyi Co. plans to reduce its shareholding by no more than 1% due to personal asset allocation needs [5] - Company Xinyi Co. was established in April 1996, specializing in the research, production, and sales of functional new materials based on organic synthetic resins [6] Group 4 - Company Xinhua Pharmaceutical received approval for the registration of ibuprofen suspension drops, a non-prescription drug for relieving fever and mild to moderate pain in children [7] - Company Xinhua Pharmaceutical was founded in November 1998, focusing on the sales of raw materials and intermediates, as well as chemical products [8] Group 5 - Company Emei Mountain A elected Tong Jianming as a director and appointed him as the general manager [9] - Company Emei Mountain A was established in October 1997, primarily engaged in tourism services, including ticket sales and hotel operations [10] Group 6 - Company Heng Rui Medicine announced the approval of its innovative drug, Regaglitin Metformin tablets, for market launch, aimed at improving blood sugar control in type 2 diabetes patients [11] - Company Heng Rui Medicine was founded in April 1997, focusing on the research, production, and sales of pharmaceuticals [12] Group 7 - Company Chongqing Rural Commercial Bank announced the approval of Tang Li's qualification as vice president [13] - Company Chongqing Rural Commercial Bank was established in June 2008, focusing on inclusive finance and corporate financial services [14] Group 8 - Company Weili Medical received certification from the Canadian Ministry of Health for its extraction bag, allowing legal sales in the Canadian market [15] - Company Weili Medical was founded in April 2004, specializing in the research, production, and sales of medical devices in various fields [16] Group 9 - Company Ailis received approval for its KRAS G12C inhibitor, a new drug for treating advanced non-small cell lung cancer [17] - Company Ailis was established in March 2004, focusing on innovative drug research and development in oncology [18] Group 10 - Company Renfu Pharmaceutical received registration certificates for two new drugs, including methylprednisolone tablets and hydrocodone ibuprofen tablets [19] - Company Renfu Pharmaceutical was founded in March 1993, focusing on the research, production, and sales of pharmaceuticals [20] Group 11 - Company Siwei Tuxin received multiple invention patent certificates from the National Intellectual Property Administration [21] - Company Siwei Tuxin was established in December 2002, focusing on navigation maps, intelligent driving, and automotive electronic chips [22] Group 12 - Company Changhong High-Tech received a warning letter from the Ningbo Securities Regulatory Bureau for failing to disclose related party transactions [23] - Company Changhong High-Tech was founded in June 2012, focusing on the research, production, and sales of styrene thermoplastic elastomers [24] Group 13 - Company Gansu Energy Chemical announced the resignation of its director and general counsel due to organizational adjustments [25] - Company Gansu Energy Chemical was established in December 1996, focusing on coal mining and sales [26] Group 14 - Company Shanghai Construction received land use rights for a residential project in Tianjin, with a total investment of approximately 330 million yuan [27] - Company Shanghai Construction was founded in June 1998, focusing on construction, design consulting, and real estate development [28] Group 15 - Company Chengdu Xian Dao announced that a major shareholder plans to increase its stake in the company by 25 to 50 million yuan [29] - Company Chengdu Xian Dao was established in February 2012, focusing on drug research and development services [30] Group 16 - Company Hunan Silver announced the resignation of its deputy general manager due to organizational adjustments [31] - Company Hunan Silver was founded in November 2004, focusing on the smelting and sales of silver and other precious metals [32] Group 17 - Company China Chemical reported a total contract amount of 123.017 billion yuan for the first four months of the year [33] - Company China Chemical was established in September 2008, focusing on construction engineering and modern services [34] Group 18 - Company Borui Pharmaceutical received a registration certificate for iodinated contrast agent injection [35] - Company Borui Pharmaceutical was founded in October 2001, focusing on the research and production of pharmaceutical intermediates and raw materials [36] Group 19 - Company Wanhua Chemical announced a technical transformation of its ethylene unit, aiming to diversify raw materials and enhance competitiveness [37] - Company Wanhua Chemical was established in December 1998, focusing on the research, production, and sales of polyurethane and fine chemicals [38] Group 20 - Company ST Houlv received approval for its injectable cephalosporin sodium to pass the consistency evaluation for generic drugs [39] - Company ST Houlv was founded in June 2005, focusing on drug research, production, and sales [40] Group 21 - Company Anka Intelligent announced a targeted reduction of capital for its subsidiary [41] - Company Anka Intelligent was established in May 2004, focusing on the research and development of power system solutions [42] Group 22 - Company Huaming Intelligent announced financial support for its subsidiary [43] - Company Huaming Intelligent was founded in August 2001, focusing on intelligent systems and services [44] Group 23 - Company Foton Motor received a central subsidy of 124 million yuan for promoting new energy vehicles [45] - Company Foton Motor was established in August 1996, focusing on vehicles and mobile equipment [46] Group 24 - Company Guangsheng Tang received a registration certificate for ritonavir tablets, used in HIV treatment [47] - Company Guangsheng Tang was founded in June 2001, focusing on the research and production of antiviral drugs [48] Group 25 - Company Kexing Pharmaceutical received FDA approval for clinical trials of its GB18 injection in the United States [49] - Company Kexing Pharmaceutical was established in August 1997, focusing on the research and production of recombinant protein drugs [50] Group 26 - Company Heng Rui Medicine announced the final price for its H-share public offering at 44.05 HKD per share [51] - Company Heng Rui Medicine was founded in April 1997, focusing on the research, production, and sales of pharmaceuticals [52] Group 27 - Company Wandong Medical elected a new chairman following the resignation of the previous chairman [53] - Company Wandong Medical was established in May 1997, focusing on the research, production, and sales of medical imaging equipment [54] Group 28 - Company Qixia Construction announced a plan to reduce its shareholding by no more than 3% [55] - Company Qixia Construction was founded in December 1999, focusing on real estate development and management [56] Group 29 - Company Dasheng Intelligent signed a contract worth 11.5 million yuan for a high-efficiency machine room project [57] - Company Dasheng Intelligent was established in March 1995, focusing on AIoT intelligent management platforms [58] Group 30 - Company Huashi Technology announced an extension of the detention period for its actual controller [59] - Company Huashi Technology was founded in June 1998, focusing on information system integration and technical services [60] Group 31 - Company Tianzhihang announced plans to increase capital for its subsidiary [61] - Company Tianzhihang was established in October 2010, focusing on orthopedic surgical navigation robots [62] Group 32 - Company Pingzhi Information signed a procurement framework agreement with China Mobile for base station antennas [63] - Company Pingzhi Information was founded in November 2002, focusing on communication equipment and services [64] Group 33 - Company Mengke Pharmaceutical received acceptance for its new drug application for a new antibacterial drug [65] - Company Mengke Pharmaceutical was established in August 2012, focusing on small molecule drug research [66] Group 34 - Company Kede Education announced a change in its actual controller to a state-owned asset supervision committee [67] - Company Kede Education was founded in January 2003, focusing on education services [68] Group 35 - Company Jinlong Automobile elected a new chairman following the board meeting [69] - Company Jinlong Automobile was established in October 1996, focusing on the production and sales of buses [70] Group 36 - Company Jushen Co. received dividends totaling 95.7 million yuan from its subsidiaries [71] - Company Jushen Co. was founded in November 2011, focusing on logistics and warehousing services [72] Group 37 - Company Qingyun Technology announced plans for shareholders to reduce their holdings by up to 4.5% [73] - Company Qingyun Technology was established in April 2012, focusing on cloud computing products and services [74] Group 38 - Company Shengdexintai received a procurement notice from Dongfang Electric for a project worth 234 million yuan [75] - Company Shengdexintai was founded in October 2001, focusing on the production and sales of energy equipment [76] Group 39 - Company Juzhi Technology announced a plan for a director to reduce his holdings by up to 400,000 shares [77] - Company Juzhi Technology was established in November 2007, focusing on machine vision equipment [78] Group 40 - Company Sanrenxing announced plans for shareholders to reduce their holdings by up to 3% [79] - Company Sanrenxing was founded in August 2003, focusing on integrated marketing services [80] Group 41 - Company Transsion Holdings announced plans to increase capital for its subsidiary by 70 million yuan [81] - Company Transsion Holdings was established in August 2013, focusing on smart terminal design and sales [82] Group 42 - Company Jinling Pharmaceutical received approval for its raw material drug for iron deficiency anemia [83] - Company Jinling Pharmaceutical was founded in September 1998, focusing on drug manufacturing and healthcare services [84] Group 43 - Company Xiyu Tourism announced plans for shareholders to reduce their holdings by up to 3% [85] - Company Xiyu Tourism was established in January 2001, focusing on tourism and scenic area management [86]

证券代码：000756 证券简称：新华制药 公告编号：2025-33 山东新华制药股份有限公司 关于取得布洛芬混悬滴剂药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或 重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药品监督管理 局核准签发的布洛芬混悬滴剂(15ml:0.6g，30ml:1.2g)（以下简称"本品"）《药品注册证书》。现将相 关情况公告如下： 一、基本情况 药品名称：布洛芬混悬滴剂 剂型：口服混悬剂 申请人：山东新华制药股份有限公司 申请事项：药品注册（境内生产） 受理号：CYHS2303314、CYHS2303315 药品批准文号：国药准字 H20254094、国药准字H20254095 通知书编号：2025S01279、2025S01280 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关 要求，批准注册，发给药品注册证书。同意本品按（甲类）非处方药管理。质量标准、说明书、标签 及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 二 ...

证券代码：000756 证券简称：新华制药 公告编号：2025-32 山东新华制药股份有限公司 关于二十碳五烯酸乙酯获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 近日，山东新华制药股份有限公司（"新华制药"或"本公司"）收到国家药品监督管理 局核准签发的二十碳五烯酸乙酯《化学原料药上市申请批准通知书》。现将相关情况公告如 下： 通知书编号：2025YS00375 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、 其他相关信息 一、基本情况 药品名称：二十碳五烯酸乙酯 剂型：原料药 注册分类：化学药品 申请人：山东新华制药股份有限公司 申请事项：境内生产化学原料药上市申请 受理号：CYHS2360419 登记号：Y20230000457 2023 年 6 月，新华制药向国家药品监督管理局递交二十碳五烯酸乙酯境内生产化学原 料药上市申请注册申报资料并获受理， 2025 年 5 月获得《化学原料药上市申请批准通知 书》，审评结论为 ...

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the market launch of Eicosapentaenoic Acid Ethyl Ester as a chemical raw material drug [1] Group 1 - The application for the domestic production of Eicosapentaenoic Acid Ethyl Ester was submitted in June 2023 and was accepted [1] - The approval notification was granted in May 2025, with a review conclusion of registration approval [1]

Core Viewpoint - Quality is fundamental to enterprise development and a key competitive advantage, as demonstrated by the recognition of three companies in the second quality-leading enterprise evaluation in Zibo High-tech Zone [1] Group 1: Company Overview - Shandong Yinuowei Polyurethane Co., Ltd. focuses on three major industrial chains: epoxy propane, epoxy ethane, and hexanedioic acid derivatives, with products applied across various sectors including light industry, construction, and healthcare [1][2] - The company has set a quality goal of "zero defects, zero complaints, zero returns," emphasizing customer satisfaction as the sole measure of work quality [2] Group 2: Quality Management and Innovation - Yinuowei has established a comprehensive quality management model that includes management manuals, procedural documents, and a structured responsibility system to enhance management levels [2] - The company has received significant support from government departments for innovation and quality improvement, including the establishment of a postdoctoral research workstation and engineering technology research center [2] Group 3: Financial Performance - In 2024, Yinuowei achieved a revenue of 6.857 billion yuan and a net profit of approximately 177 million yuan, both showing year-on-year growth [3] Group 4: Future Development Goals - By 2025, Yinuowei aims to achieve zero accidents in safety production and zero defects in products, while enhancing process technology and implementing lean management practices [4]

Group 1: Mergers and Acquisitions - The new regulations for major asset restructuring of listed companies have been officially launched, indicating the full implementation of the "six measures for mergers and acquisitions" [2] - The revised management measures support cross-industry mergers that align with business logic, establish a phased payment mechanism for restructuring shares, and encourage private equity funds to participate in mergers and acquisitions [2] - The introduction of a simplified review process for eligible listed companies significantly shortens the review timeline and improves disclosure requirements [2] Group 2: Currency and Trade - The Chinese yuan has shown signs of appreciation, with the central bank setting the mid-price below 7.2 for the first time since early April, following positive developments in Sino-US trade talks [4] - The dollar index experienced a significant drop of 10%, while Asian currencies appreciated by 5% to 10%, indicating a potential shift towards "de-dollarization" [4][5] - The U.S. Treasury Secretary indicated that countries not engaging in sincere negotiations will receive tariff notifications, with tariffs reverting to levels seen on April 2 [3] Group 3: Financial Markets - In April, foreign investors made a record net inflow of 8.21 trillion yen (approximately 406.6 billion RMB) into Japanese stocks and long-term bonds, marking the largest monthly net inflow since 1996 [6] - The rapid growth of bond ETFs has been noted, with the total market size surpassing 260 billion RMB, reflecting a shift towards more stable investment tools amid increased market volatility [10][11] Group 4: Corporate Developments - The CEO of Novo Nordisk has been dismissed, impacting the company's stock price, which fell by 2.69% following the announcement [17] - The company reported a total revenue of 78.087 billion Danish kroner (approximately 11.216 billion USD) for Q1 2025, an 18% year-on-year increase, with a significant portion of revenue coming from the blockbuster drug semaglutide [17] Group 5: Market Dynamics - The A-share market showed resilience with the Shanghai Composite Index rising by 0.76% and the ChiNext Index increasing by 1.38% during the week [13] - In the Hong Kong market, major indices experienced declines, with the Hang Seng Index dropping by 0.46% amid disappointing quarterly earnings from large tech and financial stocks [14]